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The incidence of gestational breast cancer (GBC) is increasing in high-income countries.
Our study aimed to examine the epidemiology, management and outcomes of women with
GBC in New South Wales (NSW), Australia.
Methods
A retrospective cohort study using linked data from three NSW datasets. The study group
comprised women giving birth with a first-time diagnosis of GBC while the comparison
group comprised women giving birth without any type of cancer. Outcome measures
included incidence of GBC, maternal morbidities, obstetric management, neonatal mortality,
and preterm birth.
Results
Between 1994 and 2013, 122 women with GBC gave birth in NSW (crude incidence 6.8/
100,000, 95%CI: 5.6–8.0). Women aged�35 years had higher odds of GBC (adjusted odds
ratio (AOR) 6.09, 95%CI 4.02–9.2) than younger women. Women with GBC were more
likely to give birth by labour induction or pre-labour CS compared to women with no cancer
(AOR 4.8, 95%CI: 2.96–7.79). Among women who gave birth by labour induction or pre-
labour CS, the preterm birth rate was higher for women with GBC than for women with no
cancer (52% vs 7%; AOR 17.5, 95%CI: 11.3–27.3). However, among women with GBC,
preterm birth rate did not differ significantly by timing of diagnosis or cancer stage. Babies
born to women with GBC were more likely to be preterm (AOR 12.93, 95%CI 8.97–18.64),
low birthweight (AOR 8.88, 95%CI 5.87–13.43) or admitted to higher care (AOR 3.99, 95%
CI 2.76–5.76) than babies born to women with no cancer.
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Conclusion
Women aged�35 years are at increased risk of GBC. There is a high rate of preterm birth
among women with GBC, which is not associated with timing of diagnosis or cancer stage.
Most births followed induction of labour or pre-labour CS, with no major short term neonatal
morbidity.
Introduction
In 2018, breast cancer was the most commonly diagnosed cancer in women, globally repre-
senting 24.2% of all cancers in women, and the most common cause of cancer-related mortal-
ity in women [1]. In Australia, breast cancer is the second most common cancer diagnosed
during pregnancy after melanoma, with an incidence of 7.3 per 100,000 women giving birth
[2]. The incidence of gestational breast cancer (GBC), defined as a first-time diagnosis of
breast cancer during pregnancy, is increasing in high-income countries, in part due to the
increasing age of mothers [3–5].
Women with GBC have higher rates of adverse obstetric outcomes, including thromboem-
bolic events, sepsis, induction of labour and pre-labour cesarean section [2, 6, 7]. Preterm
birth has been identified as the main adverse neonatal outcome for babies born to women with
GBC [7]. It has been reported that preterm birth is a risk factor for developmental problems,
irrespective of whether or not a baby is born to a women with GBC [8, 9]. Decisions around
preterm delivery in the majority of cases of GBC are taken without any obvious clinical indica-
tion [10]. This is concerning as it has been suggested that preterm birth is the main risk factor
for developmental problems in babies born to women with GBC irrespective of whether or not
they were exposed to chemotherapy during pregnancy [7].
Our study aimed to examine the incidence, timing of diagnosis, obstetric management and
perinatal outcomes of women with a first-time diagnosis of breast cancer during pregnancy
(GBC) and their babies in New South Wales (NSW), Australia. We also examined whether
decisions to deliver preterm babies iatrogenically by labour induction or pre-labour caesarean
section (CS) were associated with the timing of breast cancer diagnosis during pregnancy and/
or the stage of cancer at diagnosis.
Methods
We conducted a population-based cohort study using linked NSW Health data. The study
population included all women with pregnancies that ended in live birth or stillbirth in NSW
between 1 January 1994 and 31 December 2013. Birth was defined as the delivery of an infant
of at least 400 grams birthweight or at least 20 weeks gestation whether live or stillborn [11].
For this study, gestational breast cancer (GBC) was defined as a first-time diagnosis of primary
breast cancer during pregnancy.
The study group comprised all eligible pregnancies with GBC. The comparison group com-
prised women who delivered with no history of cancer before or during pregnancy (Fig 1).
We used three linked datasets: Perinatal Data Collection (PDC), the NSW Cancer Registry
(NSWCR) and the Admitted Patient Data Collection (APDC). The PDC is a state-wide surveil-
lance system that captures data relating to patterns of pregnancy care, services and outcomes
for all births in NSW (whether in public or private hospitals or home births) [12]. The
NSWCR is a population-based cancer registry that captures demographic, incidence, cancer
stage and death information of all people diagnosed with cancer (excluding non-melanoma
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skin cancers) in NSW [12]. The APDC provides information on discharges, transfers or deaths
on all patients admitted to all hospitals in NSW (public, private, repatriation and psychiatric
hospitals). APDC data were only available from July 2001 [12]. The NSW Centre for Health
Record Linkage (CHeReL) performed the data linkage. Details of the data linkage process are
available on the CHeReL website [13]. The PDC was used as the primary dataset to identify the
study cohort (NSW pregnancies from 1994 to 2013) while the NSWCR was used to identify
the group of women with GBC in the study cohort. The APDC was merged based on the
babies’ Project-specific Person Numbers (PPN) [13] and was used to determine the frequency
of hospital admissions and any diagnoses during the neonatal period for babies born to
women with GBC.
Data relating to the degree of spread of cancer was obtained from NSWCR and was catego-
rized as follows: stage 0—carcinoma in situ; stage 1—cancer localized to the tissue of origin;
stage 2—cancer that has spread to the regional lymph nodes and/or adjacent organs; and stage
3—distant metastasis. We modified these data staging categories so as to reconcile them with
the Royal College of Pathologists of Australasia cancer staging classification system. That is,
final cancer staging was determined as follows: stage 1 cancer localized to the tissue of origin;
stages 2–3 cancer that has spread to the regional lymph nodes and/or adjacent organs (the
chest wall and/or the skin); stage 4 involves distant metastasis [12, 14]. Our dataset did not
include information on stage 0 cancer, carcinoma in situ (CIS).
We classified women giving birth in NSW into three groups:
i. The study group (GBC group) comprised women with a first-time diagnosis of breast cancer
during pregnancy;
ii. The comparison group comprised women without a history of cancer before or during
pregnancy;
Fig 1. Selecting the study and comparison groups.
https://doi.org/10.1371/journal.pone.0245493.g001
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iii. An excluded group that comprised women with any type of cancer (including breast can-
cer) diagnosed prior to pregnancy (as prior cancer and its treatment may affect pregnancy
outcomes [15, 16]) and women with cancer other than breast cancer diagnosed during
pregnancy (as any decisions on their pregnancy management may not have differed from
those for women with GBC).
Main outcome measures
Maternal outcomes included pregnancy and birth management and complications (induction
of labour, caesarean section (CS)), pregnancy complications (gestational diabetes and gesta-
tional hypertension) and maternal mortality. Neonatal outcomes included perinatal death
(stillbirth or neonatal death), preterm birth (<37 weeks gestation), low birthweight (<2500
gm), small for gestational age (SGA) (birthweight below the 10th percentile for the age and sex
[17]), intraventricular haemorrhage, and respiratory distress syndrome of newborn.
Statistical analysis
The chi-squared test was used to compare the prevalence of SGA between preterm and term
babies born to women with GBC. Mann–Whitney U test was used to examine the difference in
median gestational age at birth between women with GBC and women with no cancer. Inde-
pendent samples t-test was used to compare the mean difference in maternal age and baby
birthweight between the study and comparison groups.
A Poisson regression model was used to examine the estimated increase in the incidence of
GBC each year. The indirect age-standardized rate was used to account for the increasing
maternal age during the study period when examining the incidence of GBC. As our data com-
prised population data, we used all women giving birth during the study period as a standard
population for the calculation of the indirect age-standardized rate.
Binary logistic regression models were used to identify independent factors associated with
dichotomous outcomes. Analysis of neonatal outcomes was limited to singleton births due to
the small number of multiple pregnancies (1.6%), the lack of data on the second baby in twin
pregnancies and to avoid the confounding effect of multiple pregnancies [18]. These models
incorporated all factors associated with each outcome in univariable analyses (p<0.20). Poten-
tial confounders including maternal age, parity, plurality, pre-existing chronic conditions such
as diabetes and hypertension, previous CS, smoking during pregnancy, hospital sector (public
or private) and remoteness of residence were also included. Odds ratio (OR), adjusted odds
ratio (AOR), and 95% confidence interval (CI) were calculated and variables with a statistical
level of significance (P-value) of<0.05 were considered significant. We consulted with clini-
cians in the research team, including an obstetrician, a breast surgeon, a neonatologist and an
oncologist, to determine which interactions were plausible and limited our investigations to
these. All variables in a regression models were assessed for collinearity with a variance infla-
tion factor (VIF) threshold of<3. We tested the interaction term between pre-existing hyper-
tension and smoking during pregnancy, and there was no evidence of interactions (Wald-test
p>0.05). Data analysis was undertaken using Statistical Package for Social Sciences (SPSS) ver-
sion 25.0 (IBM Corp, New York, United States).
Ethics approval
NSW Population & Health Services Research Ethics Committee provided the ethical approval
for the project (reference HREC/17/CIPHS/11).
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Results
There were 122 women with a first-time diagnosis of breast cancer during pregnancy (GBC
group) and 1,782,994 women who gave birth without a history of any type of cancer before or
during pregnancy (Fig 1).
Incidence of GBC
The crude incidence rate of GBC in NSW from 1994 to 2013 was 6.8 diagnoses of GBC per
100,000 women giving birth (Fig 2). The incidence of GBC increased from 5.8 per 100,000
women giving birth in 1994 to 7.3 per 100,000 women giving birth in 2013, reaching a peak of
13.6 per 100,000 women giving birth in 2011. This represents an average annual increase of
2.8% (95%CI: -0.3%– 5.9%) per year. However, this increasing trend in incidence was not sig-
nificant (p = 0.075).
Maternal characteristics
Age. The mean (SD) age of women with GBC was significantly higher than that of women
giving birth with no cancer (34.8 ± 4.4 years vs 29.6 ± 5.6 years, p<0.001; mean difference 5.27
years (95%CI 4.48–6.1)). The odds of GBC among women aged�35 years was six times the
odds for those aged<35 years (AOR 6.09, 95%CI 4.02–9.20) (Table 1). Among women with
GBC, there were 16 (13%) aged less than 30 years, 33 (27%) aged between 30 to 34 years, 54
(44%) between 35 to 39 and 19 (16%) aged 40 years or over.
Timing of diagnosis and stage of cancer. Of the 122 women with GBC, 25 (20.5%) were
diagnosed in the first trimester, 39 (32.0%) in the second and 58 (47.0%) in the third trimester.
Data on cancer stage were available for 113 (92.6%) and missing for 9 (7.4%). Of the 113
women with a known cancer stage, 42 (37.2%) were stage 1, 64 (56.6%) stages 2–3, and 7
(6.2%) stages 4 cancer.
First-time mothers. Women with GBC were less likely to be first-time mothers (nulli-
para) than women in the comparison group (32% vs 41.8%). However, when adjusting for age
Fig 2. Crude, indirect age-standardized incidence rate with upper and lower limits for 95%CI of the indirect age-standardized incidence
rate of breast cancer diagnosis during pregnancy in NSW 1994–2013 per 100,000 women giving birth.
https://doi.org/10.1371/journal.pone.0245493.g002
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and other maternal characteristics, the association was not significant (AOR 1.09, 95%CI:
0.70–1.68) (Table 1).
Pregnancy complications and obstetric management (mode and timing of
birth)
There were no significant differences in the rates of gestational diabetes, gestational hyperten-
sion or hospital transfer for women with or without GBC (Table 2).
Table 1. Maternal characteristics and pre-existing conditions.
Breast Cancer N = 122 No cancer (N = 1,782,994) OR (95% CI) AOR (95% CI)
Country of birth
Other countries 40(32.8) 517504(29) Reference
Australia 82(67.2) 1260229(70.7) 0.84 (0.58–1.23) 1.17 (0.76–1.79)
Not stated� 0(0) 5261(0.3)
Maternal age
<35 49(40.2) 1431525(80.3) Reference
= >35 73(59.8) 350771(19.7) 6.08 (4.23–8.73) 6.16 (4.09–9.27)
Not stated� 0(0) 698(0)
Parity
Nullipara 39(32) 744494(41.8) Reference Reference
Para 1+ 83(68) 1036047(58.1) 1.53 (1.05–2.24) 1.08 (0.7–1.67)
Not stated� 0(0) 2453(0.1)
Plurality
Singleton 120(98.4) 1756474(98.5) Reference Reference
Multiple pregnancy 2(1.6) 26520(1.5) 1.1 (0.27–4.47) 0.52 (0.07–3.73)
Previous CS
No previous CS 86(70.5) 1369535(76.8) Reference Reference
CS 1+ 18(14.8) 193811(10.9) 1.48 (0.89–2.46) 0.97 (0.57–1.68)
Not stated� 18(14.8) 219648(12.3)
Smoking during pregnancy
No 118(96.7) 1502063(84.2) Reference Reference
Yes 4(3.3) 275928(15.5) 0.18 (0.07–0.50) 0.29 (0.11–0.79)
stated� 0(0) 5003(0.3)
Pre-existing hypertension
No 118(96.7) 1767310(99.1) Reference Reference
Yes 4(3.3) 15684(0.9) 3.82 (1.41–10.35) 2.43 (0.77–7.69)
Pre-existing diabetes
No 122(100) 1772966(99.4) NA NA
Yes 0(0) 10028(0.6) NA NA
Remoteness
Major Cities 101(82.8) 1354589(76) Reference Reference
Inner Regional 17(13.9) 308563(17.3) 0.74 (0.44–1.24) 0.99 (0.57–1.75)
Outer Regional 3(2.5) 88797(5) 0.45 (0.14–1.43) 0.74 (0.23–2.35)
Remote/very remote 1(0.8) 12583(0.7) 1.07 (0.15–7.64) 2.14 (0.3–15.47)
Not stated� 0(0) 18462(1)
OR: crude odds ratio, AOR: adjusted odds ratio
�Not included in the analysis
#No previous birth.
https://doi.org/10.1371/journal.pone.0245493.t001
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Birth intervention. Among women with GBC, 51 (41.8%) had labour induction; of these,
41 (80.4%) had a vaginal birth and 10 (19.6%) gave birth by CS (Table 2). After adjusting for
maternal characteristic, pre-existing conditions and hospital sector (public or private), women
with GBC had significantly higher odds of labour induction (AOR 4.40, 95%CI 2.63–7.38) and
CS (AOR 2.46, 95% CI 1.57–3.86) than women without cancer (Table 2).
Labour induction and pre-labour CS. Ninety-three (76.2%) women with GBC gave birth
either by labour induction or pre-labour CS compared to 695,101 (39%) in the control group.
After adjusting for maternal characteristics, pre-existing conditions and hospital sector, the
odds of labour induction or pre-labour CS were significantly higher in the GBC group (AOR
4.96, 95% CI 3.06–7.79) (Table 2).
Table 2. Obstetric management and pregnancy complications by cancer status.
Outcome Breast cancer No cancer (reference) OR(95% CI) AOR(95% CI)�
Induction of labour
No 29(23.8) 1087440(61)
Yes 51(41.8) 438172(24.6) 4.36 (2.77–6.89) 4.40 (2.63–7.38)
Not applicable (Pre-labour CS)�� 42(34.4) 256929(14.4)
Not stated� 0(0) 453(0)
Induction of labour or pre-labour CS
No 29(23.8) 1087440(61)
Yes 93(76.2) 695101(39) 5.02 (3.31–7.61) 4.96 (3.06–8.05)
Preterm 48(51.6) 46855(6.7)
Term 45(48.4) 648116(93.2)
Not stated 0(0.0) 130(0.0)
Not stated 0(0) 453(0)
Mode of birth
Vaginal birth��� 67(54.9) 1330464(74.6)
Birth By CS 55(45.1) 451638(25.3) 2.42 (1.69–3.46) 2.46 (1.57–3.86)
Not stated 0(0) 892(0.1)
Gestational diabetes
No 117(95.9) 1701488(95.4)
Yes 5(4.1) 81506(4.6) 0.89 (0.36–2.18) 0.57 (0.21–1.56)
Gestational Hypertension
No 118(96.7) 1674225(93.9)
Yes 4(3.3) 108769(6.1) 0.52 (0.19–1.41) 0.55 (0.20–1.51)
Hospital sector
Public 86(70.5) 1395153(78.2)
Private 36(29.5) 387799(21.7) 1.51 (1.02–2.22) 1.11 (0.72–1.73)
Not stated�� 0(0) 42(0)
Transferred to another hospital
No 118(96.7) 1723181(96.6)
Yes 4(3.3) 59053(3.3) 0.99 (0.37–2.68) 1.40 (0.50–3.92)
Not stated�� 0(0) 760(0)
OR: crude odds ratio, AOR: adjusted odds ratio
�All variables are adjusted for maternal characteristics
��Not included in the analysis
���Including breech and instrumental birth.
https://doi.org/10.1371/journal.pone.0245493.t002
PLOS ONE Gestational breast cancer in New South Wales
PLOS ONE | https://doi.org/10.1371/journal.pone.0245493 January 22, 2021 7 / 13
Among women who gave birth by labour induction or pre-labour CS, there was a higher
rate of preterm birth in women with GBC (n = 48, 51.6%) compared to women with no cancer
(n = 46,855, 6.7%) p<0.001.
Timing of diagnosis, stage of cancer and birth by labour induction or pre-labour CS.
Among the 93 women with GBC who gave birth by labour induction or pre-labour CS, 10
(10.8%) were diagnosed in the first trimester, 32 (34.4%) in the second trimester, and 51
(54.8%) in the third trimester. Of those women diagnosed in the third trimester, 39 (76.5%)
were diagnosed before 37 weeks gestation. Seven (70%) of the women diagnosed in the first tri-
mester gave birth prematurely compared to 19 (59%) of the women diagnosed in the second
trimester and 22 (56%) of the women diagnosed in the third trimester before 37 weeks gesta-
tion. However, the rate of preterm birth among women diagnosed in the second and third tri-
mester (<37 weeks) was not significantly different from that in women diagnosed in the first
trimester (OR 0.63, 95%CI: 0.14–2.88 and OR 0.55, 95%CI: 0.12–2.47 respectively) (S1 Table).
Among the 93 women with GBC who gave birth by labour induction or pre-labour CS,
there were 27 (29.0%) with cancer stage 1, 54 (58.1%) with stages 2–3, and 6 (6.5%) with stages
4. Cancer stage was not known for 6 (6.5%). Fourteen (52%) of the women with stage 1 deliv-
ered prematurely compared to 31 (57%) of the women with stages 2–3 and 1 (17%) of the
women with stages 4. The rate of preterm delivery among women with cancer stages 2–3 or
stages 4 was not significantly different from that in women with cancer stage 1 (OR 1.25, 95%
CI: 0.49–3.17 and OR 0.19 95%CI: 0.02–1.81 respectively) (S1 Table).
Neonatal outcomes
The 122 pregnancies resulted in the birth of 120 singletons and two sets of twins. Table 3
describes the neonatal outcomes for 120 singleton babies born to women with GBC and
902,653 singleton babies born to women with no cancer. There were no stillbirths or neonatal
deaths among babies born to women with GBC. Babies born to women with GBC were more
likely to, require a high level of resuscitation including intermittent positive pressure respira-
tion and external cardiac massage (11% vs 5%, AOR 2.01, 95%CI: 1.12–3.62). They are also
more likely to be admitted to special care nursery (SCN) or neonatal intensive care unit
(NICU) (42% vs 15% AOR, 3.74, 95%CI: 2.58–5.43) than babies born to women with no can-
cer. However, after adjusting for preterm birth, there is no significant difference in the odds of
the need for a high level of resuscitation or admission to NICU/SCN between babies born to
women with GBC versus those who were born to women with no cancer (AOR, 0.98 (95%CI:
0.54–1.81) and AOR,1.28 (95%CI: 0.81–2.02) respectively). Four neonates had major neonatal
morbidities; one baby had congenital cardiomyopathy and three (34, 34 and 33 weeks’ gesta-
tion) had respiratory distress syndrome of newborn, two of whom required prolonged ventila-
tory support.
The median gestational age at birth for babies born to women with GBC was lower than
that for babies born to women with no cancer (37 weeks (IQR 35–38) vs 39 weeks (IQR 38–
40), p< 0.001). The odds of preterm birth were higher in babies born to women with GBC
(AOR 12.93, 95% CI 8.97–18.64).
The mean birthweight for live-born singletons to women with GBC was significantly lower
than that for those born to women with no cancer (2,905 ± 634 g vs 3,409 ± 546 g, p<0.001).
The birthweight distribution for preterm babies in both groups is shown in S2 Table.
Preterm birth in babies born to women with GBC. There were 53 (44.2%) preterm
births among the 120 singletons born to women with GBC. Of these, 22 (42%) were born by
induction of labour and 26 (49%) were born by pre-labour CS. Thirty-five (66%) of the pre-
term births were late preterm born between 34 and 36 weeks gestation, 17 (32.1%) were
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moderately preterm (32–33 weeks gestation), and 1 (1.9%) was early preterm (<32 weeks ges-
tation) (S2 Table).
The mean birthweight of preterm babies born to women with GBC (2,469 ± 453 g) was sig-
nificantly lower than term babies (3,250 ± 539 g) (p<0.001). Among the preterm babies of
women with GBC, there were 29 (54.7%) babies with birthweight <2500 grams compared to 3
(4.5%) among term babies (p<0.001). However, among babies of women with GBC, the preva-
lence of SGA was lower for preterm compared with term babies (1.9% vs 18.8%, p = 0.004).
Table 3. Neonatal outcomes for singleton babies by maternal cancer status.
Outcome Breast cancer No cancer (reference) OR(95% CI) AOR(95% CI)�
Sex of baby
Male 59(49.2) 903557(51.4)
Female 61(50.8) 851876(48.5) 1.10 (0.77–1.57) 1.10 (0.77–1.57)
Indeterminate�� 0(0) 222(0)
Not stated�� 0(0) 819(0)
Preterm birth
No 67(55.8) 1654251(94.2)
Yes 53(44.2) 101834(5.8) 12.85 (8.96–18.43) 13.17 (9.14–18.96)
Not stated 0(0) 389(0)
Small for gestation���
No 108(90) 1568077(89.8)
Yes 12(10) 178297(10.2) 0.98 (0.54–1.78) 1.18 (0.65–2.16)
Birthweight<2500 g��
No 88(73.3) 1668218(95.5)
Yes 32(26.7) 77482(4.4) 7.85 (5.24–11.77) 9.1 (6.02–13.77)
Not stated�� 0(0) 674(0)
5 min Apgar���
>7 115(95.8) 1686705(96.6)
7 or less 5(5.8) 54000(4.1) 1.36 (0.56–3.33) 1.32 (0.54–3.24)
Not stated 0(0) 5669(6.2)
High resuscitation���#
No 86(71.7) 1305741(74.8)
Yes 13(10.8) 91537(5.2) 2.16 (1.20–3.87) 2.01 (1.12–3.62)
Not stated�� 21(17.5) 349096(20)
Admitted to SCN/NICU for 4 hours or more���
No 70(58.3) 1480563(84.8)
Yes 50(41.7) 264646(15.2) 4.00 (2.78–5.75) 3.74 (2.58–5.43)
Not stated�� 0(0) 1165(0.1)
Discharge status
Discharged 113(94.2) 1664307(94.8) NA NA
Stillborn 0(0) 10100(0.6)
Neonatal death 0(0) 3965(0.2)
Transferred 7(5.8) 77088(4.4)
Not stated 0(0) 1014(0.1)
OR: crude odds ratio, AOR: adjusted odds ratio
�All variables are adjusted for maternal characteristics (5 min Apgar, High resuscitation and Admitted to SCN/NICU are also adjusted to the method of birth)
��Not included in the analysis
���live birth only
# intermittent positive pressure respiration and external cardiac massage
https://doi.org/10.1371/journal.pone.0245493.t003
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Hospital admissions during the neonatal period. Of the 120 singletons born to women
with GBC, hospitalization data were available for 102 (85%). Of these, 53 (52%) had at least
one hospital admission within 28 days of birth (44 had one admission, 6 had two admissions,
and 3 had three admissions).
Discussion
We found an overall incidence of GBC in NSW between 1994 and 2013 of 6.8 per 100,000
women giving birth and that women with GBC had higher rates of planned preterm birth
either by induction of labour or a pre-labour CS compared to women with no cancer. Surpris-
ingly, the rate of planned preterm birth for women with GBC was not impacted by the timing
of diagnosis or stage of cancer. Babies born to women with GBC were more likely to be pre-
term, require a high level of resuscitation and be admitted to SCN or NICU. In contrast, the
proportion of SGA for preterm babies was very low at 1.9%, suggesting planned preterm birth
for maternal management. There were no stillbirths or neonatal deaths among these babies,
and the prevalence of major neonatal morbidities was relatively low.
Our results revealed a 20-year trend of increasing GBC incidence but that this trend was
not statistically significant.
The odds of GBC were six times higher among women aged�35 years compared to those
<35 years of age. Furthermore, women with GBC were significantly older than women with
no cancer—women aged�35 years, comprised 59.8% of the GBC group compared to only
19.7% of the no cancer group.
In agreement with previous studies [3, 19, 20], our results show that women with GBC have
higher rates of labour induction and/or delivery by CS than women with no cancer. It has
been argued that the higher rates of labour induction and pre-labour CS in GBC are due to
management decisions relating to the stage of cancer at diagnosis [21]. However, our results
showed no differences in the odds of preterm labour induction or pre-labour CS among
women diagnosed at different trimesters or with different stages of cancer at diagnosis. None-
theless, these results should be interpreted with caution owing to the relatively low incidence
rate of GBC and the small number of cases of GBC in this study. Additionally, as we were not
able to obtain data relating to cancer treatment, we could not determine whether management
decisions relating to treatment were associated with increased rates of labour induction and
pre-labour CS.
There was a high rate of preterm birth among women with GBC. The majority of these
births were planned and considered iatrogenic from a neonatal perspective. This is consistent
with the high rate of preterm labour among women with GBC previously reported by Loibl
and colleagues in 2012 where they argued that decisions to initiate early iatrogenic birth are
often taken in the absence of a clear clinical indication [10]. In our study, we were unable to
show any association between the high rate of iatrogenic preterm birth and any specific cancer
stage or timing of diagnosis. This finding supports the views of Loibl and colleagues. However,
owing to the small number of cases in our study, this finding should be treated with caution.
Preterm babies, whether born to women with GBC or to women with no cancer, have
higher rates of adverse neonatal outcomes than babies born at� 37 weeks [22]. Thus, in our
cohort preterm babies of women with GBC had lower birthweights and increased rates of
resuscitation and admission to SCN/NICU than term babies. Preparing, and then caring, for a
preterm baby is demanding and inevitably places any mother at increased risk of anxiety and
stress [23]. Women with GBC already experience high levels of fatigue and sleep disturbance
underpinned by both the side effects of chemotherapy (whether given during pregnancy or
after birth) and psychological and biological factors [24–26]. Caring for a preterm baby who
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has increased needs is likely to present unique challenges to mothers coping with cancer symp-
toms in parallel with treatment side effects. These factors, together with the potential longer-
term impacts of low birthweight and neonatal complications associated with premature birth,
suggest that decisions regarding pre-term induction of labour or pre-labour CS in women
with GBC needs to be carefully considered. A delicate balance is required to be drawn between
any potential benefits to the mother of commencing early cancer treatment and the potential
adverse effects of preterm birth both to the mother and her child.
Current literature suggests that having gestational cancer or cancer treatment during preg-
nancy may be associated with a higher risk of SGA [6, 10]. However, our results do not support
this, possibly due to the small sample size of women with GBC which may have impacted the
power of the study to detect any such difference.
Although our data show a low prevalence of major neonatal morbidities in our preterm
babies, we did not have data to examine the long-term developmental effect of these infants.
Amant and colleagues (2015) previously found that preterm babies born to women with a
diagnosis of cancer during pregnancy are more likely to have long term developmental prob-
lems whether or not they were exposed to chemotherapy while in utero [7]. Given this, it is
important to promote a term birth where clinically possible in order to avoid the potential neg-
ative effects of preterm birth on both the mother and her baby.
Strengths and limitations
An important strength of our study was the population-based design that included all births in
NSW over a 20-year period from which we identified all women with invasive breast cancer
during pregnancy. Limitations include the lack of information on Indigenous status, and
breast cancer treatment. The latter has limited our ability to examine the maternal and perina-
tal outcomes by exposure to treatment. The third limitation was resultant from the fact that,
early pregnancy loss before 20 weeks’ gestation is out of the scope of the perinatal data
collection.
Conclusions
The odds of GBC were six times higher among women aged�35 years compared to those <35
years of age. There was a high rate of preterm birth among women with GBC, which could not
be explained by the timing of breast cancer diagnosis or stage of cancer at diagnosis. Spontane-
ous onset of labour of preterm birth was uncommon with most births following induction of
labour or pre-labour CS. This had a minimal impact in the short-term as major neonatal mor-
bidity was uncommon.
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